Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AbbVie reports positive hidradenitis suppurativa drug trial data

AbbVie reports positive hidradenitis suppurativa drug trial data

16th October 2014

AbbVie has announced new findings from Pioneer II, a clinical trial assessing its drug Humira as a treatment for the chronic skin condition hidradenitis suppurativa.

The therapy was able to meet its primary efficacy endpoint in the study by reducing common clinical signs and symptoms among moderate-to-severe hidradenitis suppurativa patients, specifically the number of abscesses and inflammatory nodules.

Results from this study will be used to support the company's efforts to secure regulatory approval for Humira in this new indication, in combination with previous data from the Pioneer I trial.

Hidradenitis suppurativa is a painful and chronic inflammatory skin disease that affects around one percent of the world's adult population, with no currently approved treatment options available.

Dr John Medich, vice-president for immunology clinical development at AbbVie, said: "We are encouraged by these positive results from the Pioneer trials, which add to the wealth of Humira's clinical trial experience over the past 17 years."

Humira has seen double-digit sales growth this year and remains one of AbbVie's most commercially important products.ADNFCR-8000103-ID-801754677-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.